Treatment and Diagnosis of MOG-Associated Disorders in Pediatric vs Adult: E. Ann Yeh, MD
June 2nd 2025The professor of pediatrics in neurology at the University of Toronto discussed differences in disease course, treatment strategy, and trial challenges of MOG-associated disorders in pediatric versus adult patients. [WATCH TIME: 5 minutes]
Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS
June 2nd 2025The assistant professor of neurology at Barrow Neurological Institute talked about the lack of public awareness for hypertension among individuals with MS despite many meeting diagnostic criteria. [WATCH TIME: 6 minutes]
Starting Comprehensive Multiple Sclerosis Care at Initial Diagnosis: Mary R. Rensel, MD, FAAN, ABIHM
May 31st 2025The associate professor of medicine at the Cleveland Clinic Lerner College of Medicine highlighted the importance of early, multidisciplinary intervention for patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Identifying and Treating Progression in MS Beyond Relapses: Celia Oreja-Guevara, MD, PhD
May 30th 2025The vice chair of neurology at the Hospital Clínico San Carlos in Madrid highlighted the growing importance of detecting and managing progression in multiple sclerosis, particularly PIRA. [WATCH TIME: 6 minutes]
Why Choose a DORA? Clinical Considerations for Patients With Insomnia
May 30th 2025A panelist discusses how clinicians choose between sleep aids like dual orexin receptor antagonists (DORAs) and other medications based on patient comorbidities, chronicity of insomnia, and adverse effect profiles, with DORAs offering a safer, long-term solution for patients with chronic insomnia and sleep maintenance issues.
Challenges in and Advice for Prescribing Subcutaneous Infusion Systems for Parkinson Disease
May 30th 2025Panelists discuss how challenges in prescribing subcutaneous infusion systems might affect patient adherence and device management, best practices for patient education, and what additional data would benefit clinicians implementing newer Parkinson disease treatments.
From Trials to Treatment: Understanding the Treatment Profile of Daridorexant
May 30th 2025A panelist discusses how dual orexin receptor antagonists (DORAs) are effective for treating both sleep initiation and maintenance insomnia, with a generally favorable adverse effect profile, though patients should be informed about potential risks like parasomnia-like behaviors, and the importance of patience and adherence for optimal results.
Emerging Therapies and Valuable Insights for Facilitating REST in Epilepsy
May 30th 2025A panelist discusses how midazolam autoinjectors provide an effective, fast-acting solution for rapid eye seizure termination (REST) in emergency settings, emphasizing the importance of proper education, timely use, and monitoring for adverse effects such as sedation or respiratory depression.
Clinical Pearls for CIDP Management
May 29th 2025Panelists discuss how physicians can improve outcomes for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) by prioritizing early and accurate diagnosis, personalizing treatment plans, regularly monitoring patients, and addressing the psychological and emotional impact of the disease.
Place of Recent Approvals in Parkinson Disease Management
Panelists discuss how recent approvals of novel delivery systems are reshaping the treatment landscape for Parkinson disease by addressing unmet needs in managing motor fluctuations.
Clinical Experience With CSAI for Parkinson Disease
Panelists discuss how their clinical experience with continuous subcutaneous infusion therapies has informed their approach to integrating these treatments into existing regimens, including strategies for medication adjustments and valuable lessons from European clinical practice that could benefit US clinicians.
Overviewing Phase 2 Data of Imlifidase in Guillain-Barré Syndrome: Elisabeth Sonesson, PhD
May 27th 2025The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]
Counseling About Insomnia Medications Q6
May 23rd 2025A panelist discusses how managing chronic insomnia often requires tailored treatments like dual orexin receptor antagonists (DORAs), which offer long-term benefits for sleep maintenance without the risk of tolerance or rebound insomnia, while emphasizing patient counseling and realistic expectations for gradual improvement.